Literature DB >> 29779547

Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.

Rebecca L Haffajee1, Amy S B Bohnert2, Pooja A Lagisetty3.   

Abstract

At least 2.3 million people in the U.S. have an opioid use disorder, less than 40% of whom receive evidence-based treatment. Buprenorphine used as part of medication-assisted treatment has high potential to address this gap because of its approval for use in non-specialty outpatient settings, effectiveness at promoting abstinence, and cost effectiveness. However, less than 4% of licensed physicians are approved to prescribe buprenorphine for opioid use disorder, and approximately 47% of counties lack a buprenorphine-waivered physician. Existing policies contribute to workforce barriers to buprenorphine provision and access. Providers are reticent to prescribe buprenorphine because of workforce barriers, such as (1) insufficient training and education on opioid use disorder treatment, (2) lack of institutional and clinician peer support, (3) poor care coordination, (4) provider stigma, (5) inadequate reimbursement from private and public insurers, and (6) regulatory hurdles to obtain the waiver needed to prescribe buprenorphine in non-addiction specialty treatment settings. Policy pathways to addressing these provider workforce barriers going forward include providing free and easy-to-access education for providers about opioid use disorders and medication-assisted treatment, eliminating buprenorphine waiver requirements for those licensed to prescribe controlled substances, enforcing insurance parity requirements, requiring coverage of evidence-based medication-assisted treatment as essential health benefits, and providing financial incentives for care coordination across healthcare professional types-including behavioral health counselors and other non-physicians in specialty and non-specialty settings. SUPPLEMENT INFORMATION: This article is part of a supplement entitled The Behavioral Health Workforce: Planning, Practice, and Preparation, which is sponsored by the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration of the U.S. Department of Health and Human Services.
Copyright © 2018 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29779547      PMCID: PMC6330240          DOI: 10.1016/j.amepre.2017.12.022

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  82 in total

1.  Final rules under the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008; technical amendment to external review for multi-state plan program. Final rules.

Authors: 
Journal:  Fed Regist       Date:  2013-11-13

2.  How the affordable care act and mental health parity and addiction equity act greatly expand coverage of behavioral health care.

Authors:  Kirsten Beronio; Sherry Glied; Richard Frank
Journal:  J Behav Health Serv Res       Date:  2014-10       Impact factor: 1.505

3.  A Stronger Treatment System for Opioid Use Disorders.

Authors:  Brendan Saloner; Joshua Sharfstein
Journal:  JAMA       Date:  2016 May 24-31       Impact factor: 56.272

4.  Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids.

Authors:  Raminta Daniulaityte; Russel Falck; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2011-10-28       Impact factor: 4.492

5.  Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009.

Authors:  Robert P Schwartz; Jan Gryczynski; Kevin E O'Grady; Joshua M Sharfstein; Gregory Warren; Yngvild Olsen; Shannon G Mitchell; Jerome H Jaffe
Journal:  Am J Public Health       Date:  2013-03-14       Impact factor: 9.308

6.  A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine.

Authors:  David A Fiellin; Declan T Barry; Lynn E Sullivan; Christopher J Cutter; Brent A Moore; Patrick G O'Connor; Richard S Schottenfeld
Journal:  Am J Med       Date:  2013-01       Impact factor: 4.965

7.  Factors affecting willingness to provide buprenorphine treatment.

Authors:  Julie Netherland; Michael Botsko; James E Egan; Andrew J Saxon; Chinazo O Cunningham; Ruth Finkelstein; Mark N Gourevitch; John A Renner; Nancy Sohler; Lynn E Sullivan; Linda Weiss; David A Fiellin
Journal:  J Subst Abuse Treat       Date:  2008-08-20

8.  Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.

Authors:  Erik W Gunderson; Xin-Qun Wang; David A Fiellin; Benjamin Bryan; Frances R Levin
Journal:  Addict Behav       Date:  2010-01-18       Impact factor: 3.913

9.  Distance traveled and cross-state commuting to opioid treatment programs in the United States.

Authors:  Andrew Rosenblum; Charles M Cleland; Chunki Fong; Deborah J Kayman; Barbara Tempalski; Mark Parrino
Journal:  J Environ Public Health       Date:  2011-07-06

Review 10.  Primary care models for treating opioid use disorders: What actually works? A systematic review.

Authors:  Pooja Lagisetty; Katarzyna Klasa; Christopher Bush; Michele Heisler; Vineet Chopra; Amy Bohnert
Journal:  PLoS One       Date:  2017-10-17       Impact factor: 3.240

View more
  52 in total

1.  Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016.

Authors:  Melanie S Askari; Silvia S Martins; Pia M Mauro
Journal:  J Subst Abuse Treat       Date:  2020-05-11

2.  Geographic location of buprenorphine-waivered physicians and integration with health systems.

Authors:  Brendan Saloner; LeeKai Lin; Kosali Simon
Journal:  J Subst Abuse Treat       Date:  2020-05-12

3.  ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder.

Authors:  Ryan Marino; Jeanmarie Perrone; Lewis S Nelson; Timothy J Wiegand; Evan S Schwarz; Paul M Wax; Andrew I Stolbach
Journal:  J Med Toxicol       Date:  2019-08-14

4.  Financing Buprenorphine Treatment in Primary Care: A Microsimulation Model.

Authors:  Jonathan E Fried; Sanjay Basu; Russell S Phillips; Bruce E Landon
Journal:  Ann Fam Med       Date:  2020-11       Impact factor: 5.166

5.  The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.

Authors:  Alex K Gertner; Allison G Robertson; Hendree Jones; Byron J Powell; Pam Silberman; Marisa E Domino
Journal:  Health Serv Res       Date:  2020-03-12       Impact factor: 3.402

6.  Offering Emergency Buprenorphine Without a Prescription.

Authors:  Payel Jhoom Roy; Michael D Stein
Journal:  JAMA       Date:  2019-07-08       Impact factor: 56.272

7.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

8.  Responding to the opioid and overdose crisis with innovative services: The recovery community center office-based opioid treatment (RCC-OBOT) model.

Authors:  Robert D Ashford; Austin M Brown; Jessica McDaniel; Jenna Neasbitt; Chad Sobora; Robert Riley; Lesley Weinstein; Aaron Laxton; Justin Kunzelman; Kyle Kampman; Brenda Curtis
Journal:  Addict Behav       Date:  2019-06-21       Impact factor: 3.913

9.  Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.

Authors:  Jennifer Miles; Jason Howell; Dave Sheridan; George Braucht; Amy Mericle
Journal:  Am J Drug Alcohol Abuse       Date:  2020-02-24       Impact factor: 3.829

10.  Primary Care Providers And Specialists Deliver Comparable Buprenorphine Treatment Quality.

Authors:  Alex K Gertner; Allison G Robertson; Byron J Powell; Hendree Jones; Pam Silberman; Marisa Elena Domino
Journal:  Health Aff (Millwood)       Date:  2020-08       Impact factor: 6.301

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.